Boric acid for refractory candida glabrata vaginitis

Journal of Obstetrics and Gynaecology

Volumn 26, Issue 6, 2006, Pages 584-

  Dhingra, S ^a,b   Roseblade, C K ^a  

^a WREXHAM MAELOR HOSPITAL   (United Kingdom)

^b NONE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN; BORIC ACID; FLUCONAZOLE; FLUCYTOSINE; ITRACONAZOLE;

ADULT; ARTICLE; CANDIDA GLABRATA; CASE REPORT; DRUG SAFETY; FEMALE; FUNGUS CULTURE; HUMAN; NONHUMAN; PRIORITY JOURNAL; SYMPTOMATOLOGY; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VAGINA SMEAR; VAGINITIS;

BORIC ACIDS; CANDIDA GLABRATA; CANDIDIASIS; FEMALE; HUMANS; MIDDLE AGED; VAGINITIS;

EID: 33749000295     PISSN: 01443615     EISSN: 13646893     Source Type: Journal    
DOI: 10.1080/01443610600831217     Document Type: Article

References (4)

1. Fidel PL Jr, Vazquez JA, Sobel JD. 1999. Candida glabrata: review of epidemiology, pathogenesis, and clinical disease with comparison to C. albicans. Clinical Microbiology Reviews 12:80-96.
2. Kerridge D, Nicholas RO. 1986. Drug resistance in the opportunistic pathogens Candida albicans and Candida glabrata. Journal of Antimicrobial Chemotherapy 18(Suppl. B):39-49.
3. Redondo-Lopez V, Lynch M, Schmitt C et al. 1990. Torulopsis glabrata vaginitis: clinical aspects and susceptibility to antifungal agents. Obstetrics and Gynecology 76:651-655.
4. Sobel JD, Chaim W. 1997. Treatment of torulopsis vaginitis: Retrospective review of boric acid therapy. Clinical Infectious Diseases 24:649-52.